Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

Longzhen Cui, Yan Liu, Yifan Pang, Tingting Qian, Liang Quan, Zhiheng Cheng, Yifeng Dai, Xu Ye, Ying Pang, Jinlong Shi, Xiaoyan Ke, Depei Wu, Lin Fu*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    2 Citations (Scopus)

    Abstract

    Relapsed and refractory acute myeloid leukemia (R/R AML) has complicated pathogenesis. Its treatment is complicated, and the prognosis is poor. So far, there is no consensus on what is the optimal treatment strategy. With the deepening of research, new chemotherapy regimens, new small molecule inhibitors, and immunotherapy have been increasingly applied to clinical trials, providing more possibilities for the treatment of R/R AML. The most effective treatment for patients who achieve complete remission after recurrence is still sequential conditioning therapy followed by allogeneic hematopoietic cell transplantation. Finding the best combination of treatments is still an important goal for the future.

    Original languageEnglish
    Pages (from-to)1-14
    Number of pages14
    JournalCancer Gene Therapy
    Volume27
    Issue number1-2
    DOIs
    Publication statusPublished - Feb-2020

    Keywords

    • STEM-CELL TRANSPLANTATION
    • ACUTE MYELOGENOUS LEUKEMIA
    • INTERNAL TANDEM DUPLICATION
    • NATURAL-KILLER-CELLS
    • HIGH-DOSE CYTARABINE
    • G-CSF FLAG
    • HEMATOPOIETIC STEM
    • IN-VITRO
    • T-CELL
    • PHASE-I

    Cite this